Zug-based Dotphoton, a Swiss image processing startup that uses quantum-inspired technology, has raised a pre-Series A round from Swiss private investors, as the company launches a new B2B product for biotech research, according to Venture Lab.
The company did not release the exact figure of the funding round, but did indicate that it is in the “seven figure” range.
“We are grateful to our new and existing investors for sharing Dotphoton’s vision and for helping us to build a secure and strong company. The newly raised funds will help scale Dotphoton’s image compression solutions and meet rising demand from the new customers,” said Eugenia Balysheva, CEO of Dotphoton.
According to the release, the 2020 pandemic underlined the need for remote access to the big volumes of high-quality image data. Increasing requests from biotech industrial and research laboratories showed a definite market need for JetRaw (image below), Dotphoton’s lossless raw image compression solution for biotech imagery. JetRaw enables researchers to compress raw image data up to 10 times without compromising image data quality and reduce time and budgets spent on big image data handling. PCO Imaging, a world-leading scientific camera manufacturer, collaborated with Dotphoton to commercialize JetRaw as an integrated feature in its current software. JetRaw has been validated by leading biotech research centers and is available for purchase directly from Dotphoton or through resellers starting September 10, 2020.